Controlled release matrix tablets of olanzapine: influence of polymers on the in vitro release and bioavailability.
Controlled-release (CR) tablet formulation of olanzapine was developed using a binary mixture of Methocel® K100 LV-CR and Ethocel® standard 7FP premium by the dry granulation slugging method. Drug release kinetics of CR tablet formulations F1, F2, and F3, each one suitably compressed for 9-, 12-, and 15-kg hardness, were determined in a dissolution media of 0.1 N HCl (pH 1.5) and phosphate buffer (pH 6.8) using type II dissolution apparatus with paddles run at 50 rpm. Ethocel® was found to be distinctly controlling drug release, whereas the hardness of tablets and pH of the dissolution media did not significantly affect release kinetics. The CR test tablets containing 30% Methocel® and 60% Ethocel® (F3) with 12-kg hardness exhibited pH-independent zero-order release kinetics for 24 h. In vivo performance of the CR test tablet and conventional reference tablet were determined in rabbit serum using high-performance liquid chromatography coupled with electrochemical detector. Bioavailability parameters including C(max), T(max), and AUC(0-48 h) of both tablets were compared. The CR test tablets produced optimized C(max) and extended T(max) (P < 0.05). A good correlation of drug absorption in vivo and drug release in vitro (R(2) = 0.9082) was observed. Relative bioavailability of the test tablet was calculated as 94%. The manufacturing process employed was reproducible and the CR test tablets were stable for 6 months at 40 ± 2°C/75 ± 5% relative humidity. It was concluded that the CR test tablet formulation successfully developed may improve tolerability and patient adherence by reducing adverse effects.
Badshah
Amir
A
Department of Pharmacy, University of Peshawar, Peshawar, 25120 N.W.F.P, Pakistan. amir_badshah@upesh.edu.pk
Subhan
Fazal
F
Rauf
Khalid
K
D000818:Animals; D001569:Benzodiazepines / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D001682:Biological Availability; D002482:Cellulose / Q000031:analogs & derivatives* / Q000737:chemistry; D003692:Delayed-Action Preparations / Q000138:chemical synthesis* / Q000493:pharmacokinetics; D004058:Diffusion; D004655:Emulsions / Q000737:chemistry*; D005260:Female; D008297:Male; D008747:Methylcellulose / Q000737:chemistry*; D000077152:Olanzapine; D011817:Rabbits; D013607:Tablets / Q000138:chemical synthesis* / Q000493:pharmacokinetics
D003692:Delayed-Action Preparations; D004655:Emulsions; D013607:Tablets; D001569:Benzodiazepines; C013517:ethyl cellulose; D002482:Cellulose; D008747:Methylcellulose; D000077152:Olanzapine
Pharm Res. 1998 Jun;15(6):889-96
9647355
Clin Pharmacokinet. 1999 Sep;37(3):177-93
10511917
AAPS PharmSciTech. 2010 Mar;11(1):294-303
20182827
AAPS PharmSciTech. 2008;9(1):182-90
18446480
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Aug 30;30(6):996-1008
16678954
AAPS PharmSciTech. 2006 Sep 22;7(3):78
17025258
J Chromatogr B Biomed Sci Appl. 1999 Apr 16;726(1-2):203-9
10348187
AAPS PharmSci. 2003;5(2):E13
12866940
J Am Geriatr Soc. 2004 Dec;52(12 Suppl):S272-7
15541168
J Chromatogr B Biomed Appl. 1995 Jun 9;668(1):85-90
7550985
Pharm Acta Helv. 1985;60(4):110-1
4011621
Mol Pharm. 2004 Jan 12;1(1):85-96
15832504
J Pharm Sci. 1983 Oct;72(10):1189-91
6644570
Ther Drug Monit. 1997 Jun;19(3):307-13
9200772
Ther Drug Monit. 2004 Apr;26(2):156-60
15228157
J Control Release. 2014 Sep 28;190:31-2
25356469
Schizophr Res. 2002 Oct 1;57(2-3):209-19
12223252
Int J Pharm. 2006 Apr 7;312(1-2):24-32
16481135
Ann Clin Psychiatry. 2002 Mar;14(1):47-57
12046640
Pharmacopsychiatry. 2007 May;40(3):93-102
17541883
J Control Release. 1999 Jun 2;59(3):327-42
10332064
Clin Pharmacokinet. 2007;46(5):359-88
17465637
AAPS PharmSciTech. 2007 Oct 12;8(4):E83
18181544
Psychiatr Serv. 2001 Jun;52(6):805-11
11376229
J Clin Psychiatry. 2007 Feb;68(2):e04
17335312
AAPS PharmSciTech. 2008;9(1):302-13
18446496
J Pharm Sci. 1996 Mar;85(3):330-4
8699339
Chem Pharm Bull (Tokyo). 2006 Aug;54(8):1091-6
16880650
AAPS J. 2008 Jun;10(2):261-7
18459057
J Pharm Sci. 1980 Jan;69(1):1-4
7354417
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jul;29(6):944-51
15950351
J Am Geriatr Soc. 2005 Aug;53(8):1374-9
16078964
J Control Release. 2001 Feb 23;70(3):383-91
11182208
Curr Med Res Opin. 2008 Jan;24(1):21-32
18021496
N Engl J Med. 2009 Jan 15;360(3):225-35
19144938
J Pharm Sci. 1964 Nov;53:1392-403
14253604
Drug Dev Ind Pharm. 2009 Dec;35(12):1470-8
19929206
Drug Saf. 2003;26(9):643-59
12814332
Eur J Clin Pharmacol. 1977 Dec 28;12(6):451-6
598420
Schizophr Res. 2004 Jan 1;66(1):51-7
14693352
AAPS PharmSciTech. 2008;9(3):931-8
18686038
J Pharm Sci. 1963 Dec;52:1145-9
14088963